Category: 1204-75-7

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (126 mg, 0.657 mmol) and 1-hydroxybenzotriazole monohydrate (89.0 mg, 0.657 mmol) were added to a methylene chloride solution (5.0 ml) of the resulting compound (165 mg, 0.438 mmol) and 3-hydroxyquinoxaline-2-carboxylic acid (125 mg, 0.657 mmol), at room temperature, and stirring was carried out at room temperature overnight. The reaction solution was poured into a 2N aqueous hydrochloric acid solution, followed by extraction with ethyl acetate, the extract was washed sequentially with water, a saturated aqueous sodium hydrogencarbonate solution, water and saline, and then the resulting organic layer was dried over anhydrous sodium sulfate. The organic layer was concentrated, the resulting residue was purified by a medium-pressure preparative liquid chromatograph (manufactured by Biotage, Inc., 25+M), the residue resulting from concentration was suspended in a mixed solvent of methylene chloride-dimethylether, and the solid substance was collected by filtration to afford the desired title compound (217 mg, yield 90%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.82 (1H, brs), 9.50 (1H, d, J=9.0 Hz), 7.86 (1H, t, J=7.0 Hz), 7.65-7.63 (2H, m), 7.49-7.36 (4H, m), 4.94-4.85 (2H, m), 3.71-3.61 (4H, m), 2.55 (3H, d, J=12.9 Hz), 1.96-1.84 (5H, m), 0.97-0.93 (6H, m). IR (KBr) cm-1: 2965, 1685, 1640, 1540, 1480, 1265. MS (ESI, m/z): 571 (M+Na)+. HRMS (ESI, m/z): 571.2075 (Calcd for C28H29FN6NaO5: 571.2081)., 1204-75-7

1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

The resulting compound (190 mg, 0.600 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (110 mg, 0.600 mmol) to afford N-[(1S)-1-{[4-(cyclohexyloxy)piperidin-1-yl]carbonyl}-2-methylpropyl]-3-hydroxyquinoxaline-2-carboxamide (219 mg, yield 81%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.81 (1H, brs), 9.45 (1H, t, J=8.3 Hz), 7.86 (1H, d, J=8.3 Hz), 7.63 (1H, t, J=7.5 Hz), 7.39-7.36 (1H, m), 4.86 (1H, dd, J=16.1 Hz, 9.3 Hz), 3.95-3.88 (2H, m), 3.70-3.63 (1H, m), 3.39-3.27 (3H, m), 3.19-3.06 (1H, m), 2.51-2.49 (4H, m), 1.92-1.11 (11H, m), 0.95-0.92 (6H, m). IR (ATR) cm-1: 2930, 1690, 1640, 1530, 1475, 1450, 1090. MS (ESI, m/z): 455 (M+H)+. Anal. Calcd for C25H34N4O4: C, 66.06; H, 7.54; N, 12.33. Found: C, 65.77; H, 7.47; N, 12.33., 1204-75-7

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,1204-75-7

Step S (Compound 19) [00157] 3-Hydroxy-2-quinoxaline carboxylic acid (15.0 g/78.9 mmol) was dissolved in concentrated sulfuric acid (225 ml). The reaction mixture was cooled in an ice-water bath and added slowly was Potassium nitrate (24.0 g/237.4 mmol). After completion of addition, the cooling bath was removed and the reaction mixture was allowed to reach room temperature where it was stirred overnight. The reaction mixture was poured onto ice (900 g) and the resulting precipitate was filtered. The solid was dissolved in boiling water (2.4 L) and filtered hot. Upon cooling to room temperature, the precipitated product was collected by filtration and washed with Et20. Yield: 11.40 g (62%, approximately) 1H NMR (500 MHz, DMSO-d6) 8 8.61 (s, 1H), 8. 46 (d, 1H), 7.50 (s, 1H).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; WO2005/56547; (2005); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.,1204-75-7

To a stirred solution of Cu(ClO4)2*6H2O (18.75 mg, 0.05mmol) in H2O (2 mL) was added 1 equiv. of pyrazine (4 mg,0.05 mmol) in CH3OH (5 mL). This was stirred for 5 min,and then a 5 mL CH3OH solution of 3-hydroxy-2-quinoxalinecarboxylic acid (9.5 mg, 0.05 mmol) wasadded to the reaction mixture and then filtered to givea green solution. Slow evaporation of the solvent atroom temperature gave rise to green block single crystals suitable for X-ray single-crystal analysis after ca 5 days. Yield: 40% (based on Cu). Anal. calcd forC22H20CuN6O10: C, 44.64; H, 3.41; N, 14.20%. Found: C,44.58; H, 3.49; N, 14.27%; IR (KBr)/cm-1: 3464(m),1683(s), 1609(m), 1374(m), 1326(m), 1221(w), 986(w),882(w), 806(w), 776(m), 676(m), 446(w).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Article; Liu, Qi; Wu, Huai Guang; Comptes Rendus Chimie; vol. 16; 5; (2013); p. 451 – 461;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

The resulting compound (184 mg, 0.500 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (98.0 mg, 0.500 mmol) to afford the desired title compound (115 mg, 46%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.85 (1H, brs), 9.71 (1H, brs), 7.88 (1H, dd, J=7.8 Hz, 7.4 Hz), 7.65 (1H, dd, J=7.8 Hz, 7.8 Hz), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=7.8 Hz), 7.30 (2H, d, J=9.0 Hz), 7.11 (2H, dd, J=9.0 Hz, 3.8 Hz), 5.03 (1H, m), 4.69 (1H, m), 4.04-3.72 (2H, m), 3.56-3.19 (2H, m), 2.08-1.86 (2H, m), 1.75-1.48 (2H, m), 1.32 (3H, d, J=6.6 Hz). IR (KBr) cm-1: 2945, 1685, 1640, 1620, 1505, 1240. MS (ESI, m/z): 505 (M+H)+. HRMS (ESI, m/z): 505.1686 (Calcd for C24H24F3N4O5: 505.1699).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (156 mg, 0.815 mmol) was added to a methylene chloride solution (5.4 ml) of (2S)-1-{4-[(5-fluoropyridin-3-yl)oxy]piperidin-1-yl}-3-methyl-1-oxobutan-2-amine dihydrochloride (200 mg, 0.543 mmol), 3-hydroxyquinoxaline-2-carboxylic acid (106 mg, 0.543 mmol), 1-hydroxybenzotriazole monohydrate (88.1 mg, 0.652 mmol) and N-methylmorpholine (0.299 ml, 2.72 mmol), at room temperature, and stirring was carried out at room temperature overnight. Water was added to the reaction solution, followed by extraction with methylene chloride, and the extract was washed sequentially with a saturated aqueous sodium hydrogencarbonate solution, water and saline, and dried over anhydrous sodium sulfate. After the organic layer was concentrated and the resulting residue was purified by silica gel column chromatography, the resulting residue was suspended in a mixed solvent of ethanol-diethyl ether, and the solid substance was collected by filtration to afford the desired title compound (160 mg, yield 63%) as a yellow solid. 1H-NMR (CDCl3, 400 MHz) delta: 12.56 (1H, brs), 10.12 (1H, brs), 8.20-7.99 (3H, m), 7.66-7.31 (3H, m), 7.02-6.96 (1H, m), 5.10-5.05 (1H, m), 4.70-4.61 (1H, m), 4.03-3.67 (4H, m), 2.39-1.89 (5H, m), 1.15-1.10 (6H, m). IR (KBr) cm-1: 2960, 1690, 1640, 1530, 1430. MS (ESI, m/z): 468 (M+H)+. HRMS (ESI, m/z): 490.1857 (Calcd for C24H26FN5NaO4: 490.1867). Anal. Calcd for C24H26FN5O4: C, 61.66; H, 5.61; N, 14.98; F, 4.06. Found: C, 61.44; H, 5.71; N, 14.87; F, 4.21.

1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (149 mg, 0.777 mmol) and 1-hydroxybenzotriazole monohydrate (105 mg, 0.777 mmol), were added to a methylene chloride solution (5.0 ml) of the resulting compound (180 mg, 0.518 mmol) and 3-hydroxyquinoxaline-2-carboxylic acid (148 mg, 0.777 mmol), at room temperature, under nitrogen stream, followed by further addition of triethylamine (0.289 ml, 2.07 mmol), and stirring was carried out at room temperature overnight. The reaction solution was poured into a 2N aqueous hydrochloric acid solution, followed by extraction with ethyl acetate and sequential washing with water, a saturated aqueous sodium hydrogencarbonate solution, water and saline, and then the resulting organic layer was dried over anhydrous sodium sulfate. After the organic layer was concentrated and the resulting residue was purified by a medium-pressure preparative liquid chromatograph (manufactured by Biotage, Inc., 25+M), the residue resulting from concentration was suspended in a mixed solvent of methylene chloride-diethyl ether, and the solid substance was collected by filtration to afford the desired title compound (113 mg, yield 45%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.86 (1H, s), 10.19 (1H, s), 7.97 (1H, t, J=7.0 Hz), 7.61 (1H, s), 7.53 (1H, s), 7.36 (1H, s), 7.26 (2H, t, J=7.0 Hz), 6.86 (2H, t, J=7.0 Hz), 5.09-5.07 (1H, m), 4.57-4.55 (1H, m), 4.01-3.68 (4H, m), 2.21-2.02 (5H, m), 1.14-1.11 (6H, m). IR (KBr) cm-1: 2960, 1690, 1640, 1490, 1240, 1150. MS (FAB, m/z): 483 (M+H)+. HRMS (ESI, m/z): 483.1797 (Calcd for C25H28ClN4O4: 483.1799).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (115 mg, 0.600 mmol) and 1-hydroxybenzotriazole monohydrate (91.0 mg, 0.600 mmol) were added to a methylene chloride solution (5.0 ml) of the resulting compound (160 mg, 0.500 mmol) and 3-hydroxyquinoxaline-2-carboxylic acid (98.0 mg, 0.500 mmol), at room temperature, under nitrogen stream, followed by further addition of N-methylmorpholine (0.270 ml, 2.50 mmol), and stirring was carried out at room temperature overnight. The reaction solution was diluted with methylene chloride, followed by sequential washing with a saturated aqueous sodium hydrogencarbonate solution, a saturated aqueous ammonium chloride solution, water and saline, and then the resulting organic layer was dried over anhydrous sodium sulfate. After the organic layer was concentrated and the resulting residue was purified by a medium-pressure preparative liquid chromatograph (manufactured by Biotage, Inc., 25+M), the residue resulting from concentration was suspended in a mixed solvent of methylene chloride-ethyl acetate, and the solid substance was collected by filtration to afford the desired title compound (130 mg, yield 57%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.86 (1H, brs), 9.71 (1H, brs), 7.88 (1H, dd, J=7.4 Hz, 6.8Hz), 7.65 (1H, dd, J=7.8 Hz, 7.4 Hz), 7.40 (1H, d, J=6.8 Hz), 7.38 (1H, d, J=7.8 Hz), 7.34 (2H, d, J=7.4 Hz), 7.04 (2H, m), 5.03 (1H, m), 4.66 (1H, m), 4.06-3.16 (4H, m), 2.08-1.87 (2H, m), 1.73-1.45 (2H, m), 1.31 (3H, d, J=6.6 Hz). IR (KBr) cm-1: 2945, 1690, 1640, 1500, 1240. MS (ESI, m/z): 455 (M+H)+. HRMS (ESI, m/z): 455.1478 (Calcd for C23H24ClN4O4: 455.1486).

The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The resulting compound (228 mg, 0.682 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (133 mg, 0.682 mmol) to afford the desired title compound (174 mg, yield 52%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.84 (1H, brs), 9.54 (1H, brs), 7.90-7.83 (1H, m), 7.65 (1H, dd, J=8.6 Hz, 8.2 Hz), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=8.6 Hz), 7.35-7.27 (2H, m), 7.27-7.07 (1H, m), 4.99 (1H, m), 4.59 (1H, m), 4.02-3.78 (2H, m), 3.57-3.20 (2H, m), 2.09-1.49 (6H, m), 0.92 (3H, t, J=7.0 Hz). IR (KBr) cm-1: 2940, 1685, 1640, 1505, 1210. MS (ESI, m/z): 471 (M+H)+. HRMS (ESI, m/z): 471.1848 (Calcd for C24H25F2N4O4: 471.1844).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

The resulting compound (124 mg, 0.350 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (68.6 mg, 0.350 mmol) to afford the desired title compound (74.2 mg, yield 47%) as a yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.85 (1H, brs), 9.58 (1H, d, J=7.0 Hz), 8.16 (1H, d, J=2.6 Hz), 7.88 (1H, dd, J=7.4 Hz, 5.4 Hz), 7.74-7.62 (2H, m), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=8.2 Hz), 6.93-6.84 (1H, m), 5.19 (1H, m), 5.00 (1H, m), 4.08-3.81 (2H, m), 3.58-3.16 (2H, m), 2.15-1.92 (2H, m), 1.88-1.48 (4H, m), 0.92 (3H, t, J=7.4 Hz). IR (KBr) cm-1: 2950, 1690, 1630, 1480, 1215. MS (ESI, m/z): 454 (M+H)+. HRMS (ESI, m/z): 454.1890 (Calcd for C23H25FN5O4: 454.1891).

The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider